Curated News
By: NewsRamp Editorial Staff
October 14, 2025
Soligenix Bolsters CTCL Advisory Board for HyBryte Phase 3 Development
TLDR
- Soligenix strengthens its competitive position by expanding its Medical Advisory Board to accelerate HyBryte's Phase 3 development and potential commercialization for CTCL treatment.
- Soligenix is advancing HyBryte, a photodynamic therapy using synthetic hypericin activated by visible light, through Phase 3 clinical trials for cutaneous T-cell lymphoma treatment.
- This development brings hope for improved treatment options for CTCL patients worldwide, potentially enhancing quality of life for those with this rare disease.
- Soligenix's novel photodynamic therapy uses synthetic hypericin with visible light, offering a unique approach to treating cutaneous T-cell lymphoma through targeted activation.
Impact - Why it Matters
This development matters because cutaneous T-cell lymphoma represents a significant unmet medical need with limited treatment options for patients. The advancement of HyBryte through Phase 3 trials could provide a novel, targeted photodynamic therapy that offers improved safety and efficacy compared to existing treatments. For the broader pharmaceutical landscape, Soligenix's progress demonstrates how specialized biotech companies are driving innovation in rare disease treatment, potentially setting new standards for photodynamic therapies that could eventually expand to other conditions like psoriasis. The company's dual focus on both specialized biotherapeutics and public health vaccines shows how modern biopharmaceutical companies are addressing diverse medical challenges through targeted research and development.
Summary
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, has announced significant updates to its U.S. Medical Advisory Board for cutaneous T-cell lymphoma (CTCL) to support the ongoing Phase 3 development of HyBryte™ (synthetic hypericin). The board, comprised of leading dermatologic and oncologic experts, will provide strategic guidance as Soligenix advances regulatory and commercialization activities for its innovative photodynamic therapy. President and CEO Christopher J. Schaber, PhD, emphasized that the addition of new key opinion leaders reinforces the program's clinical depth and the company's commitment to bringing HyBryte to CTCL patients worldwide. This development represents a crucial step forward in addressing unmet medical needs in rare diseases through specialized biotherapeutic approaches.
The company's Specialized BioTherapeutics business segment is advancing multiple development programs beyond CTCL, including expanding synthetic hypericin (SGX302) into psoriasis treatment and developing first-in-class innate defense regulator technology with dusquetide (SGX942) for inflammatory diseases like oral mucositis in head and neck cancer patients. Soligenix's comprehensive approach to rare disease treatment extends to their Public Health Solutions segment, which includes vaccine candidates for ricin toxin, filoviruses such as Marburg and Ebola, and CiVax™ for COVID-19 prevention. These programs leverage the company's proprietary ThermoVax® heat stabilization platform technology and have received substantial government support from agencies including NIAID, DTRA, and BARDA, demonstrating the broader significance of their research portfolio.
This announcement was distributed through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio that provides comprehensive distribution services across the biotechnology and biomedical sectors. The platform offers access to extensive wire solutions through InvestorWire, editorial syndication to thousands of outlets, enhanced press release services, and social media distribution to millions of followers. For investors and stakeholders seeking the latest updates, the company maintains an active newsroom accessible through the provided links, ensuring transparent communication about their progress in developing innovative treatments for rare diseases and public health threats.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix Bolsters CTCL Advisory Board for HyBryte Phase 3 Development
